Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
IMTX
IMTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IMTX News
Immatics Reports FY Earnings: Revenue and EPS Analysis
5d ago
seekingalpha
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
Dec 05 2025
Globenewswire
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Nov 13 2025
NASDAQ.COM
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Oct 20 2025
Newsfilter
Immatics Names Venkat Ramanan as Chief Financial Officer
Oct 01 2025
NASDAQ.COM
Immatics Names Venkat Ramanan as CFO
Oct 01 2025
Newsfilter
Guggenheim Begins Coverage of Immatics N.V. (IMTX) with a Buy Rating
Sep 19 2025
NASDAQ.COM
Fabrinet, Adecoagro, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Aug 19 2025
Benzinga
Fresh Strong Sell Stocks for August 15th
Aug 18 2025
NASDAQ.COM
Analysts Anticipate KOMP To Hit $60
Jun 24 2025
NASDAQ.COM
Immatics rises on data from early stage cell therapy trial
Jun 02 2025
SeekingAlpha
Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma
May 31 2025
NASDAQ.COM
Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation
May 29 2025
NASDAQ.COM
Clear Street Launches Healthcare & Biotechnology Equity Research
Dec 17 2024
Newsfilter
Immatics GAAP EPS of -€0.11, revenue of €50.56M
Nov 18 2024
SeekingAlpha
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Nov 08 2024
Newsfilter
Show More News
